Key Developments: Endologix Inc (ELGX.O)
14.51USD
17 May 2013
$0.49 (+3.49%)
$14.02
$14.11
$14.64
$14.00
600,164
417,613
$16.39
$11.15
Latest Key Developments (Source: Significant Developments)
Endologix Inc Reiterates FY 2013 Guidance
Endologix Inc announced that based on the first quarter 2013 results and recent developments, it is reiterating fiscal 2013 financial guidance and anticipates revenue to be in the range of $126-$133 million and a GAAP loss in 2013 of $(0.14) to $(0.17) per share, excluding the effect of increases or decreases in the Nellix contingent consideration and an Adjusted EBITDA (non-GAAP) of $0.01 to $0.05 per share in the second half of 2013. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $131 million and EPS of $(0.14) for fiscal 2013. Full Article
Endologix Inc Announces FDA Approval of First Percutaneous Indication for Endovascular Abdominal Aortic Aneurysm Repair
Endologix Inc announced that it has received U.S. Food and Drug Administration (FDA) approval of its premarket approval (PMA) supplement for a broadened indication for the Company's 21Fr profile and smaller EVAR systems to include totally percutaneous endovascular aneurysm repair (PEVAR) based upon the outcomes of the first prospective, multicenter, randomized clinical trial (The PEVAR Trial). The Endologix EVAR platforms include the Powerlink with IntuiTrak System and the AFX Endovascular AAA System, which are the first and only among commercially available endografts to achieve the totally percutaneous labeling expansion facilitated using the Perclose ProGlide Suture-Mediated Closure System made by healthcare company Abbott. The Company expects to begin training physicians in the U.S. on the PEVAR procedure in the second quarter 2013. The FDA approval provides the first clinical validation of PEVAR in a multicenter setting using the Company's fully integrated, sheath-based EVAR systems that already had the industry's only contralateral standard percutaneous (9Fr) indication. Full Article
Endologix Inc Issues FY 2013 Guidance In Line With Analysts' Estimates
Endologix Inc announced that for fiscal 2013, it expects revenue to be in the range of $126 million to $133 million, GAAP loss of ($0.14) to ($0.17) per share and an adjusted EBITDA (non-GAAP) of $0.01 to $0.05 per share. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $131 million and EPS of $(0.04) for fiscal 2013. Full Article
Endologix Inc Announces Management Change
Endologix Inc announced that it has appointed Shelley B. Thunen to the position of Chief Financial Officer, effective immediately. Ms. Thunen succeeds Robert J. Krist, who, as previously announced, has decided to retire. Mr. Krist will remain available to the Company to ensure a smooth transition. Full Article
Endologix Inc Announces Chief Financial Officer Retirement
Endologix Inc announced that Robert J. Krist, Chief Financial Officer(CFO), has decided to retire. Mr. Krist will continue to serve as the Company's CFO until a successor has been hired and will remain available to the Company as long as is required in order to ensure a smooth transition. Full Article
Endologix Inc Narrows FY 2012 Revenue Guidance; Reaffirms FY 2012 EPS Guidance
Endologix Inc announced that for fiscal 2012, it expects revenue to be in the range of $104 million to $106 million and adjusted net loss to be in the range of $(0.20) to $(0.24) per share. Full Article
Endologix Inc Reaffirms FY 2012 Revenue Guidance; Lowers FY 2012 EPS Guidance
Endologix Inc announced that based on the second quarter results, Endologix is reiterating its fiscal 2012 revenue guidance. Endologix anticipates 2012 revenue to be in the range of $102 million to $107 million. As a result of inventory charges recorded in the first half of 2012 and additional development expenses forecasted in the second half, Endologix now expects to generate a fiscal 2012 adjusted net loss of between $(0.20) to $(0.24) per share (EPS). Not included in this guidance are potential adverse litigation outcomes, fair value adjustments associated with the Nellix acquisition, or the effect of business development transactions. Full Article
Endologix Inc Reiterates FY 2012 Guidance; Comments On FY 2012 Quarterly Profit Guidance
Endologix Inc announced that based on the first quarter results, the Company is reiterated fiscal 2012 revenue and adjusted net loss per share guidance. The Company expects revenue to be in the range of $102-$107 million, adjusted Net Loss of between $(0.12) to $(0.18) per share, with quarterly progress towards profitability over the course of fiscal 2012. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $105 million and EPS of $(0.16) for fiscal 2012. Full Article
Endologix Inc Announces Chairman Change
Endologix, Inc. announced that after a 15-year career with the Company, Franklin D. Brown has announced his decision to retire as Chairman of the Board at the end of his current term. John McDermott, Endologix's President and Chief Executive Officer, has been appointed to the additional position of Chairman of the Board of Directors. The transition will be effective on the date of the Company's annual shareholder's meeting on May 24, 2012. Full Article
Endologix Inc Issues FY 2012 Guidance; EPS Guidance Below Analysts' Estimates
Endologix Inc announced that it anticipates fiscal 2012 revenue to be in the range of $102 million to $107 million. Endologix expects to generate a fiscal 2012 adjusted net loss of between $(0.12) to $(0.18) per share (EPS), with quarterly progress towards profitability over the course of the year. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $106 million and EPS of $(0.07). Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
